US
CA
NZ
UK
AU
IND
Last update at 2025-05-22T16:47:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
Thu 08 May 25, 12:30 PMALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
Fri 02 May 25, 12:00 PMWhy ALX Oncology Holdings Inc. (ALXO) Soared on Thursday
Fri 07 Mar 25, 06:27 PMALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Wed 22 Jan 25, 09:01 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -123.41800M | -83.48400M | -45.49900M | -19.20900M | -13.68600M |
| Minority interest | - | - | - | - | - |
| Net income | -123.48200M | -83.46300M | -45.74000M | -19.24300M | -13.73100M |
| Selling general administrative | 29.04M | 23.39M | 14.81M | 3.31M | 2.60M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 0.00000M | 0.00000M | 0.11M | 0.44M | 0.19M |
| Reconciled depreciation | 0.34M | 0.05M | 0.20M | 0.43M | 0.43M |
| Ebit | -127.77800M | -83.55500M | -43.66300M | -19.18300M | -13.68600M |
| Ebitda | -127.43600M | -83.47100M | -44.06700M | -18.75900M | -13.25500M |
| Depreciation and amortization | 0.34M | 0.08M | -0.40400M | 0.42M | 0.43M |
| Non operating income net other | -0.26000M | 0.08M | -1.02500M | - | - |
| Operating income | -127.43600M | -83.55500M | -43.66300M | -19.18300M | -13.68400M |
| Other operating expenses | 127.44M | 83.56M | 44.84M | 23.98M | 15.75M |
| Interest expense | -4.36000M | 0.01M | 0.81M | 0.02M | 0.00000M |
| Tax provision | 0.06M | -0.02100M | 0.24M | 0.03M | 0.04M |
| Interest income | 4.28M | - | - | 0.02M | - |
| Net interest income | 4.28M | -0.01300M | -0.81100M | -0.02100M | 0.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.06M | -0.02100M | 0.24M | 0.03M | 0.04M |
| Total revenue | 0.00000M | 0.00000M | 1.18M | 4.80M | 2.07M |
| Total operating expenses | 127.44M | 83.56M | 43.77M | 19.62M | 13.87M |
| Cost of revenue | 0.00000M | 0.00000M | 1.07M | 4.36M | 1.88M |
| Total other income expense net | 4.02M | 0.07M | -1.83600M | -0.02600M | -0.00200M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -123.48200M | -83.46300M | -45.74000M | -19.24300M | -13.73100M |
| Net income applicable to common shares | -123.48200M | -83.46300M | -50.94200M | -23.27100M | -17.40200M |
| Preferred stock and other adjustments | - | - | 5.20M | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 242.55M | 306.49M | 380.18M | 436.05M | 10.68M |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 4.92M | 4.76M | 3.35M | 1.77M | 0.26M |
| Total liab | 52.84M | 43.02M | 17.13M | 436.05M | 10.95M |
| Total stockholder equity | 189.71M | -325.46700M | -201.98500M | -118.52200M | -0.27600M |
| Deferred long term liab | - | - | 9.55M | - | - |
| Other current liab | 25.84M | 19.21M | 0.26M | 6.20M | 1.24M |
| Common stock | 0.05M | 0.04M | 0.04M | 0.04M | 0.00300M |
| Capital stock | 0.05M | 0.04M | 0.04M | 0.04M | 70.37M |
| Retained earnings | -486.27200M | -325.46700M | -201.98500M | -118.52200M | -72.78200M |
| Other liab | - | 0.05M | 1.84M | 0.00500M | 0.55M |
| Good will | - | - | - | - | - |
| Other assets | - | 9.01M | 12.27M | 0.01000M | 0.00700M |
| Cash | 22.41M | 282.91M | 363.67M | 434.22M | 9.02M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 36.00M | 28.32M | 15.29M | 6.20M | 4.98M |
| Current deferred revenue | - | - | 10.53M | - | - |
| Net debt | -5.20900M | -272.47600M | -362.92500M | -434.21900M | -3.59600M |
| Short term debt | 1.57M | 1.04M | 0.74M | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 17.20M | 10.43M | 0.74M | - | 5.42M |
| Other stockholder equity | 675.68M | 0.80M | -0.04100M | 118.52M | 2.14M |
| Property plant equipment | - | 3.89M | 0.90M | 0.05M | 0.86M |
| Total current assets | 188.66M | 270.97M | 367.02M | 434.22M | 9.81M |
| Long term investments | 35.41M | 16.70M | - | - | - |
| Net tangible assets | - | 263.46M | 363.05M | 429.85M | -70.63900M |
| Short term investments | 160.33M | 217.38M | - | - | - |
| Net receivables | 1.00M | - | - | - | 0.54M |
| Long term debt | 9.64M | 9.39M | - | - | 5.42M |
| Inventory | - | - | - | - | - |
| Accounts payable | 8.59M | 8.07M | 3.76M | 0.00400M | 3.75M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 0.26M | -0.84500M | - | -554.61600M | -1.44900M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.04M | 0.04M | 0.04M | 0.00300M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -325.46700M | -201.98500M | -118.52200M | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 7.58M | 9.01M | 9.69M | 1.78M | 0.00700M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 53.89M | 35.52M | 13.16M | 1.83M | 0.87M |
| Capital lease obligations | 7.56M | 1.04M | 0.74M | - | - |
| Long term debt total | - | 9.39M | - | - | 5.42M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -233.98900M | -4.92300M | 0.61M | -0.35300M | -0.65300M |
| Change to liabilities | 10.56M | 3.29M | -3.74400M | 2.98M | -0.26900M |
| Total cashflows from investing activities | -235.41600M | -4.92300M | 0.61M | -0.35300M | -0.65300M |
| Net borrowings | 9.35M | -0.28100M | -6.50600M | 5.92M | 5.92M |
| Total cash from financing activities | 9.86M | 2.47M | 462.88M | 15.36M | 0.00100M |
| Change to operating activities | 5.34M | -7.31700M | 3.99M | 1.28M | 0.11M |
| Net income | -123.48200M | -83.46300M | -45.74000M | -19.24300M | -13.73100M |
| Change in cash | -314.77900M | -70.55200M | 425.20M | 0.76M | -13.84200M |
| Begin period cash flow | 363.67M | 434.22M | 9.02M | 8.26M | 22.10M |
| End period cash flow | 48.89M | 363.67M | 434.22M | 9.02M | 8.26M |
| Total cash from operating activities | -89.22300M | -68.10100M | -38.28900M | -14.24900M | -13.19000M |
| Issuance of capital stock | 0.00000M | 0.00000M | 472.94M | 9.43M | 0.00000M |
| Depreciation | 0.34M | 0.05M | 0.20M | 0.43M | 0.43M |
| Other cashflows from investing activities | - | -4.25700M | 0.64M | - | - |
| Dividends paid | - | - | -0.00300M | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | - | - | 0.54M | 0.40M | -0.93200M |
| Sale purchase of stock | 0.34M | 0.20M | 0.00300M | 0.00000M | -0.00600M |
| Other cashflows from financing activities | 9.35M | 2.55M | 101.13M | 15.35M | -0.65300M |
| Change to netincome | 23.84M | 19.34M | 6.58M | 0.30M | 0.27M |
| Capital expenditures | 1.43M | 4.92M | 0.03M | 0.35M | 0.65M |
| Change receivables | - | - | 0.54M | - | - |
| Cash flows other operating | 0.42M | -9.24000M | -1.00000M | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -314.77900M | -70.55200M | 425.20M | - | - |
| Change in working capital | 9.85M | -4.02700M | 0.25M | 4.26M | -0.15900M |
| Stock based compensation | 23.84M | 13.91M | 5.44M | 0.30M | 0.27M |
| Other non cash items | 0.23M | 5.42M | 0.29M | 0.01M | - |
| Free cash flow | -90.65000M | -73.02400M | -38.32000M | -14.60200M | -13.84300M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ALXO Alx Oncology Holdings |
0.05 11.86% | 0.46 | - | - | 5906.24 | 0.62 | 4254.36 | -2.349 |
| NVO Novo Nordisk A/S |
-0.155 0.23% | 68.05 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.95 1.40% | 68.95 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-4.41 1.01% | 430.91 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-10.3 1.70% | 594.32 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
323 Allerton Avenue, South San Francisco, CA, United States, 94080
| Name | Title | Year Born |
|---|---|---|
| Dr. Corey S. Goodman Ph.D. | Independent Exec. Chairman | 1951 |
| Dr. Jaume Pons Ph.D. | Founder, Pres, CEO & Director | 1967 |
| Mr. Peter S. Garcia M.B.A. | Chief Financial Officer | 1962 |
| Ms. Shelly Pinto | VP of Fin. & Chief Accounting Officer | 1977 |
| Dr. Sophia Randolph M.D., Ph.D. | Chief Medical Officer & Director | 1968 |
| Dr. Michael Chang Ph.D. | VP of Operations | NA |
| Dr. Chris Byrd J.D., Ph.D. | Gen. Counsel | NA |
| Ms. Jeanne Y. Jew | Chief Bus. Officer | 1964 |
| Dr. Athanasios Tsiatis M.D. | Sr. VP of Clinical Devel. | NA |
| Dr. Lin Yeong-Liang M.D., M.S. | Sr. VP of Drug Safety & Pharmacovigilance | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...